Login Register Cart 0
Generic placeholder image

Endocrine, Metabolic & Immune Disorders - Drug Targets

Editor-in-Chief

ISSN (Print): 1871-5303
ISSN (Online): 2212-3873

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Meta-Analysis

Meta-analysis of the Relationship between Type 2 Diabetes Mellitus and Renal Cancer Risk

Author(s): Yingxin Wang*, Ying Cao and Chenchen Zhu

Volume 24, Issue 7, 2024

Published on: 25 October, 2023

Page: [832 - 839] Pages: 8

DOI: 10.2174/0118715303256408230925060414

Price: $65

Abstract

Objective: This study aimed to investigate the relationship between type 2 diabetes mellitus and the risk of renal cancer.

Methods: A search was carried out on PubMed, Embase, Web of Science, China Biology Medicine disc (CBM), China National Knowledge Infrastructure (CNKI), Wanfang and other databases. The search period was from 2000 to 2022. The two authors independently conducted literature screening, extracted literature data, and then conducted a literature quality evaluation. The type of study is a cohort study. Meta-analysis was carried out on the included literature through Stata12.0 software, and the combined value was calculated with RR value and 95% confidence interval. Subgroup analysis was carried out to explore the impact of different factors on the overall results.

Results: A total of 10 articles were included. Through cohort study, the meta-analysis on the risk of type 2 diabetes and renal cancer showed that the combined effect value Risk Ratio (RR) = 1.57 with 95% Confidence Intervals (CI) (1.36, 1.82) and P<0.05. The difference had a significant impact, indicating that the risk of renal cancer in type 2 diabetes patients was 1.55 times higher than that in non-type 2 diabetes patients. The subgroup analysis showed that the combined effect value RR and 95% CI for men was 1.49 (1.26, 1.75), and the combined effect value RR and 95% CI for women was 1.60 (1.35, 1.88), which was basically consistent.

Conclusion: Type 2 diabetes can significantly increase the risk of renal cell carcinoma, and the former is a risk factor for the latter. It is suggested that multi-center studies with larger sample sizes should be conducted in the future, and adjustments should be made according to the type of diabetes, the source of the study population, the pathological type of renal cell carcinoma, the use of hypoglycemic drugs, and other factors, to provide a reliable basis for the study of the relationship between diabetes and renal cell carcinoma. At present, the specific mechanism of diabetes increasing the risk of renal cell carcinoma and whether diabetes increases mortality due to renal cell carcinoma is still unclear and needs further research.

« Previous Next »
Graphical Abstract

[1]
Sarraju, A.; Li, J.; Cannon, C.P.; Chang, T.I.; Agarwal, R.; Bakris, G.; Charytan, D.M.; de Zeeuw, D.; Greene, T.; Heerspink, H.J.L.; Levin, A.; Neal, B.; Pollock, C.; Wheeler, D.C.; Yavin, Y.; Zhang, H.; Zinman, B.; Perkovic, V.; Jardine, M.; Mahaffey, K.W. Effects of canagliflozin on cardiovascular, renal, and safety outcomes in participants with type 2 diabetes and chronic kidney disease according to history of heart failure: Results from the CREDENCE trial. Am. Heart J., 2021, 233, 141-148.
[http://dx.doi.org/10.1016/j.ahj.2020.12.008] [PMID: 33358942]
[2]
Wang, S.; Lo Galbo, M.D.; Blair, C.; Thyagarajan, B.; Anderson, K.E.; Lazovich, D.; Prizment, A. Diabetes and kidney cancer risk among post-menopausal women: The Iowa women’s health study. Maturitas, 2021, 143, 190-196.
[http://dx.doi.org/10.1016/j.maturitas.2020.07.010] [PMID: 33308628]
[3]
Xue, J.; Min, F.; Ma, F. Research on diabetes prediction method based on machine learning. J. Phys. Conf. Ser., 2020, 1684(1), 012062.
[http://dx.doi.org/10.1088/1742-6596/1684/1/012062]
[4]
Hydes, T.J.; Cuthbertson, D.J.; Graef, S.; Berhane, S.; Teng, M.; Skowronska, A.; Singh, P.; Dhanaraj, S.; Tahrani, A.; Johnson, P.J. The impact of diabetes and glucose-lowering therapies on hepatocellular carcinoma incidence and overall survival. Clin. Ther., 2022, 44(2), 257-268.
[http://dx.doi.org/10.1016/j.clinthera.2021.12.011] [PMID: 35078642]
[5]
Narayan, K.M.V.; Kondal, D.; Daya, N.; Gujral, U.P.; Mohan, D.; Patel, S.A.; Shivashankar, R.; Anjana, R.M.; Staimez, L.R.; Ali, M.K.; Chang, H.H.; Kadir, M.; Prabhakaran, D.; Selvin, E.; Mohan, V.; Tandon, N. Incidence and pathophysiology of diabetes in South Asian adults living in India and Pakistan compared with US blacks and whites. BMJ Open Diabetes Res. Care, 2021, 9(1), e001927.
[http://dx.doi.org/10.1136/bmjdrc-2020-001927] [PMID: 33771764]
[6]
Liu, L.; Gracely, E.J.; Yin, X.; Eisen, H.J. Impact of diabetes mellitus and cardiometabolic syndrome on the risk of Alzheimer’s disease among postmenopausal women. World J. Diabetes, 2021, 12(1), 69-83.
[http://dx.doi.org/10.4239/wjd.v12.i1.69] [PMID: 33520109]
[7]
Yang, K.; Xiong, G.; Li, X.; Tang, Y.; Tang, Q.; Zhang, C.; He, Z.; Zhou, L. Prevalence of baseline chronic kidney disease in 2,769 Chinese patients with renal cancer: Nephron-sparing treatment is still underutilized. World J. Urol., 2014, 32(4), 1027-1031.
[http://dx.doi.org/10.1007/s00345-013-1178-0] [PMID: 24121818]
[8]
Marble, A. Diabetes and cancer. N. Engl. J. Med., 1934, 211(8), 339-349.
[http://dx.doi.org/10.1056/NEJM193408232110801]
[9]
Wang, Z.; Yin, Y.; Wang, J.; Zhu, Y.; Li, X.; Zeng, X. Standardized incidence rate, risk and survival outcomes of second primary malignancy among renal cell carcinoma survivors: A nested case-control study. Front. Oncol., 2021, 11, 716741.
[http://dx.doi.org/10.3389/fonc.2021.716741] [PMID: 34395291]
[10]
Habib, S.L.; Liang, S. Hyperactivation of Akt/mTOR and deficiency in tuberin increased the oxidative DNA damage in kidney cancer patients with diabetes. Oncotarget, 2014, 5(9), 2542-2550.
[http://dx.doi.org/10.18632/oncotarget.1833] [PMID: 24797175]
[11]
Wu, J.J.; Fang, Z.Q.; Jia, W.S.; Zhou, F.; Chen, W.; Ye, G. Metaanalysis of the relationship between type 2 diabetes and the risk of kidney cancer. J. Reg. Anatomy Operative Surg., 2015, 2015
[12]
Renal cell carcinoma sharply captured by imaging technology at an early stage in a hemodialysis patient: Usefulness of noninvasive monochrome superb microvascular imaging. Hemodial. Int., 2021, 25(3), E26-E28.
[13]
Yangqin, Zheng diabetes mellitus%neutrophil-lymphocyte ratio%prognosis%renal cell carcinoma. Exp. Ther. Med., 2018, 17(2), 1268-1275.
[PMID: 30680002]
[14]
Lin, W.; Liu, X.J.; Wei, N.; Gao, B.X.; Jiang, G.J.; Chang, Y.Q. Systematic review of therapeutic effects of Fufang Biejia Ruangan Tablet on hepatic fibrosis. Chin. J. Gastroenterol. Hepatol., 2007, 16(1), 69-72.
[15]
Swerdlow, A.J.; Laing, S.P.; Qiao, Z.; Slater, S.D.; Burden, A.C.; Botha, J.L.; Waugh, N.R.; Morris, A.D.; Gatling, W.; Gale, E.A.; Patterson, C.C.; Keen, H. Cancer incidence and mortality in patients with insulin-treated diabetes: A UK cohort study. Br. J. Cancer, 2005, 92(11), 2070-2075.
[http://dx.doi.org/10.1038/sj.bjc.6602611] [PMID: 15886700]
[16]
Joh, H.K.; Willett, W.C.; Cho, E. Type 2 diabetes and the risk of renal cell cancer in women. Diabetes Care, 2011, 34(7), 1552-1556.
[http://dx.doi.org/10.2337/dc11-0132] [PMID: 21602426]
[17]
Zhang, P.H.; Chen, Z.W.; Lv, D.; Xu, Y.Y.; Gu, W.L.; Zhang, X.H.; Le, Y.L.; Zhu, H.; Zhu, Y.M. Increased risk of cancer in patients with type 2 diabetes mellitus: A retrospective cohort study in China. BMC Public Health, 2012, 12(1), 567.
[http://dx.doi.org/10.1186/1471-2458-12-567] [PMID: 22839452]
[18]
Lin, C.C.; Chiang, J.H.; Li, C.I.; Liu, C.S.; Lin, W.Y.; Hsieh, T.F.; Li, T.C. Cancer risks among patients with type 2 diabetes: A 10-year follow-up study of a nationwide population-based cohort in Taiwan. BMC Cancer, 2014, 14(1), 381.
[http://dx.doi.org/10.1186/1471-2407-14-381] [PMID: 24884617]
[19]
Hemminki, K.; Li, X.; Sundquist, J.; Sundquist, K. Risk of cancer following hospitalization for type 2 diabetes. Oncologist, 2010, 15(6), 548-555.
[http://dx.doi.org/10.1634/theoncologist.2009-0300] [PMID: 20479278]
[20]
Kim, S.K.; Jang, J.Y.; Kim, D.L.; Rhyu, Y.A.; Lee, S.E.; Ko, S.H.; Han, K.; Song, K.H. Site-specific cancer risk in patients with type 2 diabetes: A nationwide population-based cohort study in Korea. Korean J. Intern. Med., 2020, 35(3), 641-651.
[http://dx.doi.org/10.3904/kjim.2017.402] [PMID: 32392663]
[21]
Undzyte, G.; Patasius, A.; Linkeviciute-Ulinskiene, D.; Zabuliene, L.; Stukas, R.; Dulskas, A.; Smailyte, G. Increased kidney cancer risk in diabetes mellitus patients: A population-based cohort study in Lithuania. Aging Male, 2020, 23(5), 1241-1245.
[http://dx.doi.org/10.1080/13685538.2020.1755249] [PMID: 32342709]
[22]
Graff, R.E.; Sanchez, A.; Tobias, D.K.; Rodríguez, D.; Barrisford, G.W.; Blute, M.L.; Li, Y.; Sun, Q.; Preston, M.A.; Wilson, K.M.; Cho, E. Type 2 diabetes in relation to the risk of renal cell carcinoma among men and women in two large prospective cohort studies. Diabetes Care, 2018, 41(7), 1432-1437.
[http://dx.doi.org/10.2337/dc17-2518] [PMID: 29678810]
[23]
Ballotari, P.; Vicentini, M.; Manicardi, V.; Gallo, M.; Chiatamone Ranieri, S.; Greci, M.; Rossi, P. Diabetes and risk of cancer incidence: Results from a population-based cohort study in northern Italy. BMC Cancer, 2017, 17(1), 703.
[http://dx.doi.org/10.1186/s12885-017-3696-4] [PMID: 29070034]
[24]
Ogunleye, A.A.; Ogston, S.A.; Morris, A.D.; Evans, J.M.M. A cohort study of the risk of cancer associated with type 2 diabetes. Br. J. Cancer, 2009, 101(7), 1199-1201.
[http://dx.doi.org/10.1038/sj.bjc.6605240] [PMID: 19690547]
[25]
Koizumi, G.; Makita, Y.; Yamanaka, T. Change in proteinuria and renal function in patients with type 2 diabetes receiving standard treatment. JMJ, 2021, 67(4), 346-354.
[http://dx.doi.org/10.14789/jmj.JMJ20-OA10]
[26]
Larsson, S.C.; Wolk, A. Diabetes mellitus and incidence of kidney cancer: A meta-analysis of cohort studies. Diabetologia, 2011, 54(5), 1013-1018.
[http://dx.doi.org/10.1007/s00125-011-2051-6] [PMID: 21274512]
[27]
O’Mara, B.A.; Byers, T.; Schoenfeld, E. Diabetes mellitus and cancer risk: A multisite case-control study. J. Chronic Dis., 1985, 38(5), 435-441.
[http://dx.doi.org/10.1016/0021-9681(85)90139-0] [PMID: 3998058]
[28]
Pollak, M. Insulin and insulin-like growth factor signalling in neoplasia. Nat. Rev. Cancer, 2008, 8(12), 915-928.
[http://dx.doi.org/10.1038/nrc2536] [PMID: 19029956]
[29]
Morss, A.S.; Edelman, E.R. Glucose modulates basement membrane fibroblast growth factor-2 via alterations in endothelial cell permeability. J. Biol. Chem., 2007, 282(19), 14635-14644.
[http://dx.doi.org/10.1074/jbc.M608565200] [PMID: 17327226]
[30]
Zhang, Y.; Kang-Cai, F.U.; Tang, F.M.; Xie, K.S. The study of relationship between insulin resistance, fat and fatty liver in pa-tients with type 2 diabetes mellitus. J. Hainan Med., 2004, 2004
[31]
Ogushi, T.; Takahashi, S.; Takeuchi, T.; Urano, T.; Horie-Inoue, K.; Kumagai, J.; Kitamura, T.; Ouchi, Y.; Muramatsu, M.; Inoue, S. Estrogen receptor-binding fragment-associated antigen 9 is a tumor-promoting and prognostic factor for renal cell carcinoma. Cancer Res., 2005, 65(9), 3700-3706.
[http://dx.doi.org/10.1158/0008-5472.CAN-04-3497] [PMID: 15867365]
[32]
Sakowicz-Burkiewicz, M.; Pawelczyk, T. Recent advances in understanding the relationship between adenosine metabolism and the function of T and B lymphocytes in diabetes. J. Physiol. Pharmacol., 2011, 62(5), 505-512.
[PMID: 22204797]
[33]
Equa, Exforge, Afinitor. Three new Novartis medicines approved in Japan for patients with type 2 diabetes, high blood pressure and advanced kidney cancer. https://www.bionity.com/en/news/112187/

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy